Fredun Pharmaceuticals approves NSE equity listing application

Fredun Pharmaceuticals Limited approved an application to list and trade its equity shares on the National Stock Exchange of India Limited on November 5, 2026, subject to applicable laws, regulations and necessary approvals, while reporting standalone profit after tax of Rs 18.83 crore for the quarter ended September 30, 2026.

What did Fredun Pharmaceuticals approve for NSE?

Fredun Pharmaceuticals approved a proposal to make an application to National Stock Exchange of India Limited, or NSE, for the listing and trading of its equity shares. The board took the decision at its meeting on Thursday, November 5, 2026, which began at 10:00 a.m. and concluded at 11:10 a.m.

The approval is for an application, rather than confirmation that trading has begun on NSE. Fredun Pharmaceuticals said the step remains subject to applicable laws, regulations and necessary approvals. Its November 5 filing was addressed to BSE Limited and identified the company under BSE scrip code 539730, but did not disclose an expected date for NSE admission or commencement of trading.

What conditions remain before the NSE listing can proceed?

Fredun Pharmaceuticals said the NSE application is conditional on applicable laws, regulations and necessary approvals, without naming a timetable or describing the approval process further. The November 5, 2026 decision is therefore a board-authorised proposal rather than a disclosed completed NSE listing.

The board considered the NSE proposal in the same meeting that adopted unaudited standalone results for the quarter and half year ended September 30, 2026. Those results were reviewed by the audit committee and subjected to a limited review by statutory auditor Rakesh Nisar & Co, which issued an unmodified conclusion, according to the company’s notes.

How did Fredun Pharmaceuticals perform in the September 2026 quarter?

Fredun Pharmaceuticals reported total income from operations of Rs 267.64 crore and profit after tax of Rs 18.83 crore in the quarter ended September 30, 2026. Total income rose from Rs 228.25 crore in the preceding June 2026 quarter and Rs 145.29 crore in the September 2025 quarter, while profit after tax rose from Rs 13.17 crore and Rs 9.73 crore, respectively.

The company’s profit before tax was Rs 29.90 crore in the September 2026 quarter, compared with Rs 20.59 crore in June 2026 and Rs 13.01 crore a year earlier. Tax expense was Rs 11.08 crore, leaving the reported Rs 18.83 crore period profit. The filing recorded no exceptional or prior-period item in any of those three quarterly columns.

Expenses increased to Rs 237.73 crore from Rs 207.66 crore in the June 2026 quarter, alongside the increase in income. Material consumed was Rs 239.81 crore and finance costs were Rs 8.78 crore in the September quarter, while changes in inventories contributed a negative Rs 47.74 crore expense line. Fredun Pharmaceuticals identifies its single operating segment as pharmaceutical and healthcare, so the filing gives no separate product or geography segments.

What changed in Fredun Pharmaceuticals’ half-year results and capital?

Fredun Pharmaceuticals reported Rs 495.88 crore of total income from operations and Rs 31.99 crore of profit after tax for the half year ended September 30, 2026. In the corresponding half year ended September 30, 2025, income was Rs 265.15 crore and profit after tax was Rs 16.50 crore, making the 2026 reported figures higher in both comparisons.

The company’s basic earnings per share, or EPS, was Rs 19.05 for the half year ended September 30, 2026, against Rs 11.65 for the corresponding prior-year half year. Quarterly basic EPS was Rs 11.21 for September 2026, compared with Rs 7.96 in June 2026 and Rs 6.87 in September 2025. Fredun Pharmaceuticals stated that quarterly and half-yearly EPS figures are not annualised.

During the half year, Fredun Pharmaceuticals allotted 1,10,25,380 fully paid bonus equity shares of face value Rs 10 each on July 16, 2026, in the ratio of two shares for every one share held. It also allotted 1,60,533 equity shares following conversion of 1,60,533 warrants after receipt of applicable consideration. The company said comparative EPS was retrospectively adjusted under Indian Accounting Standard 33, or Ind AS 33, for the bonus issue.

Paid-up equity share capital stood at Rs 16.90 crore on September 30, 2026, compared with Rs 16.54 crore on June 30, 2026 and Rs 14.17 crore a year earlier. Public shareholding was reported at 56.38% on September 30, versus 55.43% at June 30 and 51.07% a year earlier. The filing listed 95,28,510 public shares and 73,71,159 non-encumbered promoter and promoter-group shares at September 30.

What does the September balance sheet show?

Fredun Pharmaceuticals reported inventories of Rs 372.45 crore as of September 30, 2026, compared with Rs 269.80 crore at March 31, 2026. Trade and other receivables increased to Rs 97.03 crore from Rs 92.69 crore, while cash and cash equivalents declined to Rs 5.15 crore from Rs 64.90 crore over the same dates.

Non-current borrowings rose to Rs 86.93 crore at September 30 from Rs 56.31 crore at March 31, while current borrowings declined to Rs 159.71 crore from Rs 165.72 crore. Property, plant and equipment was Rs 148.26 crore, up from Rs 117.61 crore, and other equity was Rs 314.42 crore, compared with Rs 273.24 crore at the prior financial year-end. These are standalone balance-sheet figures, not separate disclosure of financing linked to the proposed NSE application.

Conclusion

The November 5 board decision gives Fredun Pharmaceuticals authority to apply for listing and trading of its equity shares on NSE, but the filing does not say that NSE has approved the application or set a trading start date. The decision accompanied higher standalone income and profit for both the September 2026 quarter and the first half, as well as changes in share capital resulting from the July 16 bonus issue and warrant conversions.

The next disclosed matter to watch is the status of the NSE application and any necessary approvals, as Fredun Pharmaceuticals provided no completion target or timetable. Financially, the next comparable disclosures can show whether the September-half pattern of Rs 495.88 crore in income, Rs 31.99 crore in profit after tax, Rs 372.45 crore in inventories and Rs 246.64 crore in total borrowings continues.